GlassScriptPhysician profile
Young Eun Song
NPI 1700358116
$3,238.47
in general payments reported to CMS, 2019-2025
26 companies · $926 in 2025
The $926 reported for 2025 was more than what 83% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $607 · 2022: $645 · 2023: $335 · 2024: $726 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.25 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.73 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $390.56 | 2022-2025 | Belbuca |
| Tersera Therapeutics LLC | $213.52 | 2024-2025 | Prialt |
| Forte Bio-Pharma LLC | $155.23 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $140.66 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $138.07 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.22 | 2025 | Relistor |
| Redhill Biopharma INC. | $133.40 | 2021-2022 | |
| Pfizer INC. | $109.44 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $108.18 | 2025 | Xeomin |
| Biodelivery Sciences International, INC. | $106.87 | 2021 | |
| Nevro Corp. | $90.07 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $76.82 | 2021 | |
| Ibsa Pharma INC. | $70.25 | 2023-2025 | Tirosint, Licart, Flector |
| Horizon Therapeutics Plc | $58.82 | 2023 | Krystexxa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $56.31 | 2024 | Mild Device Kit |
| Abbott Laboratories | $53.78 | 2024 | Proclaim |
| Amgen INC. | $48.96 | 2021-2024 | Krystexxa |
| Boston Scientific Corporation | $39.42 | 2023 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $23.06 | 2022 | |
| Radius Health, INC. | $22.99 | 2021 | |
| Hikma Pharmaceuticals USA | $22.00 | 2022 | |
| Eisai INC. | $18.80 | 2021 | |
| Stryker Corporation | $18.54 | 2024 | Mild Device Kit |
| Metacel Pharmaceuticals LLC | $16.83 | 2022 | |
| Lilly USA, LLC | $15.94 | 2023 | Amyvid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Eun Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.